All News

audience learn

Day 4 Report from ACR21

d Jack Cush, MD

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Read Article
brain.mri2_.jpg

Cognitive Impairment in Patients with Rheumatoid Arthritis

d Akhil Sood, MD

Evidence suggests that RA patients are at increased risk for cognitive impairment. This is likely mediated by certain factors, including chronic inflammation and accelerated atherosclerosis. In the clinical setting, it is important to identify RA patients at increased risk for cognitive impairment.

Read Article
ACR Best

ACR21 Best Abstracts - Day 4

d Jack Cush, MD

On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.

Read Article
Malar,rash,SLE, Lupus

Predictors of Remission and Low Disease Activity in SLE

d Sheila Reyes, MD

A treat-to-target strategy has been shown to improve clinical outcomes in patients with rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis including systemic lupus erythematosus.  The goal of treatment in SLE is aimed at remission or low disease activit

Read Article
In a world where telemedicine and virtual care are not going away, is there value in patients assessing their own tender and swollen joints? Dr. David Liew ( @drdavidliew) shares data presented at #ACR21. https://t.co/6psWCAJJ9f https://t.co/mjTSrYUshp

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy complications in Ankylosis Spondylitis: Dr.Olga Petryna ( @DrPetryna) discusses abstract #0369 presented at the #ACR21 annual meeting. https://t.co/N1twEIB5Yw https://t.co/sYctM3kBBw

Links:

Dr. John Cush RheumNow ( View Tweet)
Check out my #RheumNow highlights from #ACR21 discussing OP in PsA https://t.co/dpfT7FjyjA

Dr. Rachel Tate uptoTate ( View Tweet)

RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

Perspectives on TNFi: Dr. Jon Giles Dr. Jon Giles offers his perspective and insight into data presented Saturday at #ACR21 annual meeting, specifically abstract #0457. https://t.co/efIGP5HDUQ https://t.co/2oXkcLC028

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis: "What Matters" to Patients, Physicians Dr. Swetha Ann Alexander ( @swethaann23 ) shares a summary of a poster from #ACR21 discussing what matters to patients and physicians when assessing psoriatic arthritis. https://t.co/RPTmOeasUp https://t.co/K9oCpcvmKx

Links:

Dr. John Cush RheumNow ( View Tweet)
After failing a JAK inhibitor, can you still hit a JAK-pot? Dr. Eric Dein ( @ericdeinmd) summarizes the abstracts presented at #ACR21. https://t.co/qRM7daiBmh https://t.co/yM0pT091i9

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR21 Best Abstracts - Day 2 The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2021 Day 2. https://t.co/Q6jCm29MN0 https://t.co/RTiifs5GxA

Links:

Dr. John Cush RheumNow ( View Tweet)
Management of Pain in Spondyloarthritis: Dr. Antoni Chan ( @synovialjoints ) discusses abstract #0360 presented at the #ACR21 annual meeting. https://t.co/C6QU1J6E18 https://t.co/EAfXarQ976

Links:

Dr. John Cush RheumNow ( View Tweet)
Iberdomide for Lupus: Dr. Kathryn Dao ( @KDAO2011 ) discusses abstract #1458 presented at the #ACR21 annual meeting. https://t.co/viLtTG0tzB https://t.co/rdWTXaquDS

Links:

Dr. John Cush RheumNow ( View Tweet)
JAKi For Refractory Still’s Disease: Dr. Olga Petryna ( @DrPetryna) discusses abstract #0195 presented at the #ACR21 annual meeting. https://t.co/deSxncZOVP https://t.co/OJWGd4Osc4

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

Additional analysis on Phase 2 trial of Deucravacitinib (Tyk-2 inhibitor) in PsA. n=203 (dose 6mg QD v 12mg QD v Placebo) 🔹Prior-TNF vs TNF-naive: similar Significant improvement: 🔹ACR 20/50/70 & HAQ-DI 🔹TJC/SJC/enthesitis https://t.co/RV1zLpkUQe #ACR21 Abst#1820 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Study presented by Dr. Michaela Koehm evaluated benefit of MTX in combination with ustekinmuab in PsA w/1° outcome of non-inferiority to placebo @ DAS28 @ wk 24. 🔹Randomized 173 pts 🔹52 weeks 🔹1° met (continued below) https://t.co/65ZXDjG9ur #ACR21 Abst#L12 @RheumNow https://t.co/KsBbwJuLe8

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)
Glucocorticoids (GC) in SLE on Belimumab 🔹Post-hoc, 5 phase 3 trials 🔹1° endpoint >25% pred↘️ to <7.5mg/d 🔹BEL n=1869; Placebo n=1217 🔹Baseline: 88% on GC; mean ~12.3mg/d pred 🔹Endpoint met by 17% BEL and 12% Pbo (p=0.0024) https://t.co/xp9LamlpHZ #ACR21 Abst#1283 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

#ICYMI #ACR21 Watch my interview with ⁦⁦@LatikaGupta_⁩ as she discusses the CoVAD study. @RheumNow ⁦@APLAR_org⁩ ⁦@rheumarhyme⁩ https://t.co/et0X7ltx3K

Links:

sheila RHEUMarampa ( View Tweet)

×